Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 946 to 960 of 1362 results for social care

  1. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

  2. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

  3. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued Reference number: GID-TA10495

  4. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  5. Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

    Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.

  6. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)

    Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

  7. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

  8. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

  9. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  10. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

  11. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (HTG730)

    Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.

  12. Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.

  13. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

  14. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

  15. The hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability (MIB7)

    NICE has developed a Medtech Innovation Briefing (MIB) on the hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability